Coherus Oncology, Inc. (CHRS) Operating cash flow 2016–2025
Coherus Oncology, Inc. (CHRS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$138.5MFY2025 · since FY2016: -$252.5M → -$138.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$138.5M | -577.7% |
| FY2024 | -$20.4M | +88.3% |
| FY2023 | -$174.9M | +27.5% |
| FY2022 | -$241.1M | -544.2% |
| FY2021 | -$37.4M | -124.3% |
| FY2020 | $154.1M | +443.6% |
| FY2019 | $28.4M | +117.8% |
| FY2018 | -$159.3M | +20.5% |
| FY2017 | -$200.3M | +20.7% |
| FY2016 | -$252.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice